Trial SURMOUNT-1 Trial Phase 3 multicenter, double-blind, randomized, placebo-controlled trial was conducted at 119 sites in nine countries Intervention Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or placebo, administered subcutaneously once weekly for 72 weeks as an adjunct to lifestyle intervention
It works by increasing insulin levels in your body, which decreases your blood sugar (glucose)
While initial safety concerns surrounding pancreatic and thyroid cancers led to regulatory scrutiny of incretin-based therapies, this meta-analysis of 93 RCTs shows no significant increase in pancreatic cancer risk
diaTribe does not provide medical diagnosis, advice, or treatment
While the evidence suggests a potential increase in risk, it is essential to approach this information with a nuanced understanding, recognizing that individual patient factors play a significant role